Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C

Lancet

Volumn 351, Issue 9096, 1998, Pages 83-87

  Reichard, Olle ^b,c   Norkrans, Gunnar ^d   Frydén, Aril ^e   Braconier, Jean Henrik ^a   Sönnerborg, Anders ^b   Weiland, Ola ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c DANDERYD HOSPITAL   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ABDOMINAL PAIN; ADULT; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DATA ANALYSIS; DEPRESSION; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HEPATITIS C; HUMAN; HUMAN TISSUE; HYPERTHYROIDISM; HYPOTHYROIDISM; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; VERTIGO;

EID: 0032501714     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)06088-1     Document Type: Article

References (33)

1. 1 Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. N Engl J Med 1989; 321:1501-06.
2. 2 Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. N Engl J Med 1989; 321: 1506-10.
3. 3 Chemello L, Bonetti P, Cavaletto L, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995; 22:700-06.
4. 4 Bardelli F, Messori A, Rampazzo R, Alberti A, Martini N. Effect of recombinant or lymphoblastoid interferon-alfa on alanine aminotransferase in patients with chronic hepatitis C or chronic non-A, non-B hepatitis. Clin Drug Invest 1995; 9:239-54.
5. 5 Reichard O, Foberg U, Frydén A, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alfa 2b for 60 weeks. Hepatology 1994; 19:280-85.
6. 6 Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995; 332: 1457-62.
7. 7 Lin R, Roach E, Zimmerman, Strasser S, Farrell G, for the Australia Hepatitis C Study Group. Interferon alfa-2b for chronic hepatitis C: effect of dose increment and duration of treatment on response rates. J Hepatol 1995; 23:487-96.
8. 8 Patterson JL, Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis 1990; 12: 1132-46.
9. 9 Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 1991; 337: 1058-61.
10. 10 Di Bisceglie A, Shindo M, Fong TL, et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992; 16:649-54.
11. 11 Reichard O, Yun ZB, Sönnerborg A, Weiland O. Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. J Med Virol 1993; 41: 99-102.
12. 12 Di Bisceglie A, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C. Ann Intern Med 1995; 123: 897-903.
13. 13 Camps J, Garcia N, Riezu-Boj JI, Civeira MP, Prieto J. Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon. J Hepatol 1993; 19: 408-12.
14. 14 Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996; 25:591-98.
15. 15 Brillanti S, Garson J, Foli M, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994; 107: 812-17.
16. 16 Schvarcz R, Ando Y, Sönnerborg A, Weiland O. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who failed to achieve sustained response to interferon alone: Swedish experience. J Hepatol 1995; 23(suppl 2): 17-21.
17. 17 Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol 1995; 23 (suppl 2): 8-12.
18. 18 Braconier JH, Paulsen O, Engman K, Widell A. Combined alpha-interferon and ribavirin treatment in chronic hepatitis C: a pilot study. Scand J Infect Dis 1995; 27: 325-29.
19. 19 Schalm SW, Hansen BE, Chemello L, et al. Ribavirin enhances the efficacyt but not the adverse effects of interferon in chronic hepatitis C. J Hepatology 1997; 26: 961-66.
20. 20 Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156-59.
21. 21 Tong MJ, Blatt LM, McHutchison JG, Hur Y, Co RL, Conrad A. Early prediction of response to interferon alfa-2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology (in press).
22. 22 Hawkins A, Davidson F, Simmonds P. Comparison of plasma virus loads among individuals infected with hepatitis C virus (HCV) genotypes 1, 2, and 3 by Quantiplex HCV RNA assay versions 1 and 2, Roche Monitor assay, and an in-house limiting dilution method. J Clin Microbiol 1997; 35:187-92.
23. 23 Stuyver L, Rossau L, Wyseur A, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993; 74:1093-02.
24. 24 International Group. Acute and chronic hepatitis revisited. Lancet 1977; ii: 914-19.
25. 25 Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
26. 26 Batts KP, Ludwig J. Chronic hepatitis. Am J Surg Pathol 1995; 19: 1409-17.
27. 27 Reichard O. Short-term versus sustained response to interferon therapy. Dig Dis Sci 1996; 41 (suppl 12): 109S-14S.
28. 28 Brillanti S, Foli M, Masci C, Miglioli M. Three-year follow-up of chronic hepatitis C patients treated with ribavirin plus interferon-alfa combination therapy: evidence for long-term efficacy and safety. Hepatology 1996; 24: 395A (abstract).
29. 29 Martinot-Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 1050-56.
30. 30 Yamada G, Takatani M, Kishi F, et al. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 1995; 22: 1351-54.
31. 31 Lau JY, Davis GL, Kniffen J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341:1501-04.
32. 32 Yun ZB, Reichard O, Chen M, et al. Serum hepatitis C virus RNA levels in chronic hepatitis C: importance for outcome of interferon alfa-2b treatment. Scand J Infect Dis 1994; 26: 263-70.
33. 33 Toyoda H, Nakano S, Kumada T, et al. Comparison of serum hepatitis C virus RNA concentration by branched DNA probe assay with competitive reverse transcription polymerase chain reaction as a predictor of response to interferon-alfa therapy in chronic hepatitis C patients. J Med Virol 1996; 48: 354-59.